“One of the fundamental themes of the third Si-Guida congress is thealgodystrophy. The latter it is considered a rare disease, in reality it is not that rare because it must be taken into account that probably one in three wrist fractures results in algodystrophy“. Like this John Iolascon, orthopedist and physiatrist and executive director of the Italian Society for the Unified and Interdisciplinary Management of Musculoskeletal Pain and Algodystrophy (Si Guida), on the occasion of the opening of the third national congress of the Society, underway in Rome.
“Algodystrophy is a chronic painful pathology for which the extremities of the limb are so painful that the patient has difficulty in making any movement and tolerating the activities of daily life. In our congress – said Iolascon – we will address this pathology not only from the point of view of the diagnostic and classification novelties of the disease but above all from the therapeutic point of view. In fact, today in Italy a drug has been created and produced that has this specific indication, namely the treatment of algodystrophy. This is the neridronate, produced by an Italian company, which has been authorized by AIFA and for which there is also reimbursement “.
“Therefore, people who have the diagnosis of algodystrophy, certified by dedicated clinics, can benefit from the use of this molecule which significantly reduces the impact of the disease in the affected person. In this congress we will illustrate the first results and a new formulation of the molecule will be presented which will no longer be administered only intravenously but also intramuscularly. The latter is a much simpler mode. In the last two years of the pandemic, despite having the molecule available, the fact that the patient had to go to the hospital for infusions to be treated was a limit. Today, with the presentation of the data on the efficacy of the molecule also intramuscularly – he underlined – we will give space to this new method of administration that will allow a much more extensive use. If there are still limitations in access to the hospital environment due to Covid, the possibility of having home administration with an intramuscular injection will facilitate the treatment of the disease for all the people who are affected “.